OakChart

CRISPR Therapeutics AG

CRSPHealthcare·Biotechnology·Switzerland·Mid·NASD·Nov 11 • 11:15 AM ET

45.38+0.23 (0.51%)
2026-11-11 17:15 CET
Market cap
4,379.59 USD m
Revenue, TTM
25.17 USD m
Net income, TTM
-456.13 USD m
Free cash flow, TTM
-376.71 USD m
EPS diluted, TTM
-4.75
P/E
-
Compare

Price

CRSP against its 20, 50 and 200-day averages
2050200beatmiss
45.0050.0055.0060.002.0M4.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRSPclose 45.3820-day 50.0950-day 52.66200-day 52.6445.3852w high52w low

28.5% under the 52-week high of 63.45 on 6 Jul 2026. 52-week low 44.12 on 30 Mar 2026. Last 15 sessions, 25.4% high to low

Profile

CRSP
52-week range, 7% of the way up
44.1263.45

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

IndexRUT
IPOOct 19, 2016
Beta1.91
ATR, 14d2.75
Rel volume1.96
Short float19.09%
Insider own7.16%
Inst own72.80%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap4.40B
Enterprise Value2.91B
Income-456.13M
Sales25.17M
Book/sh17.02
Cash/sh23.43
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOOct 19, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S174.89
P/B2.67
P/C1.94
P/FCF-
EV/EBITDA-
EV/Sales115.57
Quick Ratio16.21
Current Ratio16.21
Debt/Eq0.47
LT Debt/Eq0.46
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.75
EPS next Y-3.53
EPS next Q-1.17
EPS this Y30.53%
EPS next Y21.49%
EPS next 5Y32.76%
EPS past 3/5Y8.21% -4.10%
Sales past 3/5Y43.09% 37.31%
EPS Y/Y TTM14.92%
Sales Y/Y TTM-34.34%
EPS Q/Q1.19%
Sales Q/Q1325.08%
EarningsNov 02 AMC
EPS/Sales Surpr.-10.92% -14.12%

Ownership

Insider Own7.16%
Insider Trans-1.38%
Inst Own72.80%
Inst Trans-1.26%
ROA-19.00%
ROE-25.60%
ROIC-18.93%
Gross Margin-693.22%
Oper. Margin-2058.55%
Profit Margin-1812.07%
SMA20-9.40%
SMA50-13.82%
SMA200-13.78%
Trades-

Technical

Shs Outstand96.86M
Shs Float90.05M
Short Float19.09%
Short Ratio11.00
Short Interest17.19M
52W High63.45 -28.48%
52W Low44.12 2.86%
Volatility6.21% 4.94%
ATR (14)2.75
RSI (14)36.54
Beta1.91
Rel Volume1.96
Avg Volume1.56M
Volume937,791

Performance

Perf Week-12.35%
Perf Month-9.42%
Perf Quarter-15.95%
Perf Half Y-13.97%
Perf YTD-13.46%
Perf Year-17.80%
Perf 3Y-14.64%
Perf 5Y-48.38%
Perf 10Y159.31%
Recom1.87
Target Price82.74
Prev Close45.15
Price45.38
Change %0.51%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 15, 2026InitiatedUUBSNeutral$52+14.6%
Jun 11, 2026ResumedMMorgan StanleyEqual-Weight$60+32.2%
Sep 18, 2025InitiatedJJP MorganOverweight$70+54.3%
Feb 14, 2025UpgradeEEvercore ISIIn-line → Outperform$60 → $99+118.2%
Feb 12, 2025UpgradeTTD CowenSell → Hold$35-22.9%
Feb 03, 2025InitiatedHH.C. WainwrightBuy$65+43.2%
Aug 06, 2024ReiteratedNNeedhamBuy$88 → $84+85.1%
Aug 02, 2024InitiatedRRodman & RenshawBuy$90+98.3%
Jun 28, 2024ResumedGGuggenheimNeutral
Feb 15, 2024InitiatedWWolfe ResearchPeer Perform

Peers

Mkt cap
TickerCompanyMkt cap
BEAMBeam Therapeutics Inc2.62B
NTLAIntellia Therapeutics Inc1.61B
EDITEditas Medicine Inc375.82M
PRMEPrime Medicine Inc777.20M
VRTXVertex Pharmaceuticals Inc137.00B
IONSIonis Pharmaceuticals Inc4.83B
VIRVir Biotechnology Inc2.26B
ALNYAlnylam Pharmaceuticals Inc20.97B
INCYIncyte Corp24.77B
WVEWave Life Sciences Inc673.54M

Insider trading

latest 14 of 40
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RAJU PRASADOfficerNov 06 '26Proposed Sale49.8879,3933,960,183Nov 06 05:37 PM
Kulkarni SamarthChief Executive OfficerOct 19 '26Sale49.7847,8372,381,326311,899Oct 20 05:35 PM
George SimeonDirectorOct 14 '26Option Exercise14.0030,000420,00030,000Oct 16 05:45 PM
George SimeonDirectorOct 14 '26Sale49.6314,514720,37315,486Oct 16 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryOct 14 '26Sale49.261,04051,23095,857Oct 15 05:35 PM
Kulkarni SamarthChief Executive OfficerOct 14 '26Sale49.264,098201,867259,736Oct 15 05:35 PM
SIMEON GEORGEDirectorOct 14 '26Proposed Sale49.6314,514720,373Oct 14 04:16 PM
KASINGER JAMES R.General Counsel and SecretaryOct 06 '26Option Exercise13.621,99027,10496,774Oct 08 05:35 PM
KASINGER JAMES R.General Counsel and SecretaryOct 06 '26Sale60.041,990119,48194,784Oct 08 05:35 PM
JAMES KASINGEROfficerOct 06 '26Proposed Sale60.041,990119,481Oct 06 04:47 PM
KASINGER JAMES R.General Counsel and SecretarySep 22 '26Option Exercise13.6210,400141,648105,184Sep 24 05:35 PM
KASINGER JAMES R.General Counsel and SecretarySep 22 '26Sale60.2410,400626,46094,784Sep 24 05:35 PM
JAMES KASINGEROfficerSep 22 '26Proposed Sale60.2410,400626,460Sep 22 04:42 PM
Behbahani AliDirectorSep 17 '26Option Exercise14.0030,000420,00030,316Sep 21 06:40 PM

Held by

AUM
TickerCompanyAUM
ARKEARK DIET Q3 Buffer ETFAUM: 1.45M
ARKKARK Innovation ETFAUM: 5.97B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
ARKGARK Genomic Revolution ETFAUM: 1.97B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 206
  • CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) -9.77%
  • Mid-cap biotech catalysts: FDA dates, earnings, and pipeline data to watch (Investing.com)
  • CRISPR Therapeutics Presents Phase 1b Data for CTX310 Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026 (GlobeNewswire)
  • CRISPR Therapeutics Reports Phase 1 Zugo-Cel Data Showing Responses Across Autoimmune Diseases (InvestorsHub)
  • CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases (GlobeNewswire)
  • Loading…
  • CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (GlobeNewswire)
  • CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer (GlobeNewswire)
  • CRISPR Therapeutics Announces Chief Financial Officer Transition (GlobeNewswire)
  • CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 (GlobeNewswire)
  • 3 Trending Names Overtaking Wall Street Today (Schaeffer's Research) -5.82%
  • CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 (GlobeNewswire)
  • Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-02-1.150-1.037-1.15112.6714.7520
2026Q22026-08-03-0.940-1.195-0.94510.187.4519
2026Q12026-05-04-1.280-1.219-1.2801.466.0623
2025Q42026-02-12-1.370-1.163-1.3710.864.7224
2025Q32025-11-10-1.170-1.265-1.1660.899.1226
2025Q22025-08-04-2.400-1.402-2.3950.896.1424
2025Q12025-05-06-1.580-1.244-1.5830.876.2923
2024Q42025-02-11-0.440-1.201-0.43735.698.0628
2024Q32024-11-05-1.010-1.408-1.0080.606.5427
2024Q22024-08-05-1.490-1.428-1.4890.5212.0626
2024Q12024-05-08-1.430-1.361-1.4250.5023.0523
2023Q42024-02-211.1000.0661.099201.21140.9428
2023Q32023-11-06-1.410-1.989-1.4120.0611.8925
2023Q22023-08-07-0.980-2.127-0.98370.001.8025
2023Q12023-05-08-0.670-1.741-0.67510025.8521
2022Q42023-02-21-1.410-2.250-1.4120.017.1224

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.1700.0081.174289.59257.81
2020FY-5.290-5.022-5.2900.722.32
2021FY4.7004.8834.698914.96903.86
2022FY-8.360-9.088-8.3631.206.14
2023FY-1.940-2.917-1.939371.21293.21
2024FY-4.340-5.161-4.34237.3111.17
2025FY-6.470-6.213-6.4703.517.05
2026FY--4.495--35.47
2027FY--3.529--120.63
2028FY--1.967--490.83
2029FY-3.671--2,364
2030FY-17.059--6,029

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06195611.340.0056.58
2026Q4S2026-11-03194610.670.0056.58
2026Q4S2026-11-02180015.490.0075.44
2026Q4S2026-10-18180015.490.0075.44
2026Q4S2026-10-13183615.490.0075.44
2026Q4S2026-09-19173614.430.0075.44
2026Q4S2026-08-25183614.880.0075.44
2026Q4S2026-08-23183714.880.0075.44
2026Q4S2026-08-14184714.880.0075.44
2026Q4S2026-08-13184714.870.0075.44
2026Q4S2026-08-04194714.110.0075.44
2026Q4S2026-07-22181118.390.00120.82
2026Q4S2026-07-19182118.390.00120.82
2026Q4S2026-07-07185218.390.00120.82

Estimate history

EPS, annual-1.707-3.441.174-5.294.698-8.363-1.939-4.342-6.468-4.7472
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.008-0.437-1.583-2.395-1.166-1.371-1.28-0.945-1.152
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual40.9973.124289.590.719914.9631.198371.20637.3143.5125.17
Period201720182019202020212022202320242025TTM
Sales, quarterly0.60235.6910.8650.8920.8890.8641.45810.18112.669
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual40.59251.85360.78473.91576.9978.51280.04485.74295.89496.856
Period201720182019202020212022202320242025MRQ
Shares, quarterly85.33685.74286.36188.37693.87395.89496.38696.66196.856
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue25.173.5137.31371.211.20914.960.72289.593.12
Cost of Goods Sold Incl. D&A199.67232.96129.51150.09134.4217.95---
Gross Profit-174.50-229.45-92.19221.12-133.22897.01---
Selling, General and Administrative Excl. Other343.68338.87374.37443.66539.94523.48345.97238.12158.55
Research and Development278.98265.33301.39367.50437.47420.68257.76174.64113.77
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-518.18-568.32-466.57-222.54-673.16373.53-354.4446.74-158.94
Interest Expense-0.000.000.000.000.000.000.000.00
Unusual Expense16.2991.450.000.000.000.000.00-0.00
Net Income Before Taxes-453.65-577.97-362.67-150.72-650.50379.53-348.0667.31-164.43
Income Taxes2.493.633.592.89-0.331.870.810.450.55
Consolidated Net Income-456.13-581.60-366.25-153.61-650.17377.66-348.8766.86-164.98
Net Income From Continuing Operations-456.13-581.60-366.25-153.61-650.17377.66-348.8766.86-164.98
Net Income-456.13-581.60-366.25-153.61-650.17377.66-348.8766.86-164.98
EPS (Recurring)-4.60-5.76-4.34-1.94-8.364.70-5.291.17-3.44
EPS (Basic, Before Extraordinaries)-4.75-6.47-4.34-1.94-8.364.97-5.291.23-3.44
EPS (Diluted)-4.75-6.47-4.34-1.94-8.364.70-5.291.17-3.44
EBITDA-499.70-548.84-447.31-202.70-648.99391.48-345.2551.47-155.42
Non-Operating Income (Expense)80.8281.81103.9071.8222.666.006.3820.57-5.49
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense55.0457.2768.3964.0177.3874.7448.1936.1531.02
Price To Earnings Ratio-----17.15-62.70-
Price To Sales Ratio212.611,343.5088.9813.362,638.066.6614,043.8911.97438.65
Gross Margin-693.22-6,537.01-247.0859.57-11,120.5398.04---
Operating Margin-2,058.55-16,191.40-1,250.38-59.95-56,190.4040.82-49,295.5516.14-5,087.80
Net Margin-1,812.07-16,569.77-981.54-41.38-54,271.7041.28-48,520.8623.09-5,281.08
Shares Outstanding96.8695.8985.7480.0478.5176.9973.9160.7851.85
Market Capitalization4,379.594,379.593,359.514,972.473,182.665,799.2210,902.523,621.061,479.93

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue12.6710.181.460.860.890.890.8635.69
Cost of Goods Sold Incl. D&A45.4844.5750.2559.3661.5249.7562.244.84
Gross Profit-32.81-34.39-48.79-58.50-60.63-48.86-61.3830.85
Selling, General and Administrative Excl. Other85.5680.4181.4696.2671.4384.2187.0495.44
Research and Development69.7964.9566.3777.8654.5065.2967.7577.31
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-118.37-114.80-130.25-154.76-132.06-133.07-148.42-64.59
Interest Expense---0.000.000.000.000.00
Unusual Expense13.52-3.6312.10-5.70-5.5096.250.000.00
Net Income Before Taxes-111.36-90.19-122.09-130.00-105.82-207.26-134.89-36.61
Income Taxes0.070.960.840.610.621.291.110.70
Consolidated Net Income-111.44-91.15-122.93-130.61-106.44-208.55-136.00-37.31
Net Income From Continuing Operations-111.44-91.15-122.93-130.61-106.44-208.55-136.00-37.31
Net Income-111.44-91.15-122.93-130.61-106.44-208.55-136.00-37.31
EPS (Recurring)-1.05-0.97-1.19-1.41-1.21-1.62-1.58-0.44
EPS (Basic, Before Extraordinaries)-1.15-0.94-1.28-1.37-1.17-2.40-1.58-0.44
EPS (Diluted)-1.15-0.94-1.28-1.37-1.17-2.40-1.58-0.44
EBITDA-114.17-110.50-125.93-149.10-127.66-128.47-143.69-59.75
Non-Operating Income (Expense)20.5220.9820.2619.0720.7422.0713.5427.98
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.1913.6812.9014.2813.1213.9115.9717.34
Price To Sales Ratio212.61393.061,113.611,423.33154.35111.3077.6290.15
Gross Margin-259.02-337.80-3,346.43-6,770.83-6,819.57-5,477.69-7,095.9586.43
Operating Margin-934.33-1,127.55-8,933.33-17,912.50-14,854.78-14,918.27-17,158.84-180.96
Net Margin-879.60-895.33-8,431.48-15,117.25-11,973.12-23,379.93-15,722.08-104.54
Shares Outstanding96.8696.6696.3995.8993.8788.3886.3685.74
Market Capitalization4,379.595,260.324,566.024,997.545,894.504,200.732,918.913,359.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,983.461,903.831,693.691,815.322,379.131,690.33943.77456.65239.76
Short Term Receivables0.0027.10206.5011.208.7110.844.200.092.63
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.216.217.8926.5129.6815.1414.589.666.00
Total Current Assets1,985.671,937.131,908.081,853.032,417.511,716.32962.55466.39248.38
Net Property, Plant & Equipment247.57277.55305.94320.56312.0493.0372.8318.5018.86
Total Investments and Advances7.6311.5213.5664.7716.9116.855.043.163.15
Intangible Assets-0.000.020.070.120.180.230.290.34
Other Assets24.3715.831.984.645.291.5926.100.670.61
Total Assets2,265.242,242.032,229.572,243.062,751.881,827.971,066.75489.02271.35
Short Term Debt Incl. Current Port. of LT Debt18.5817.2915.6215.8412.1611.368.490.000.00
Accounts Payable11.1414.7138.1527.4314.829.095.945.071.64
Income Tax Payable1.110.450.440.140.7210.470.580.400.35
Other Current Liabilities118.2955.3354.5877.7092.1963.3342.0922.2712.53
Total Current Liabilities149.1287.78108.79121.11119.8894.2657.1127.7514.51
Long Term Debt188.17206.41223.01228.18212.8750.0744.050.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities6.1415.7714.9718.2919.6619.4126.1769.0869.00
Total Liabilities343.43309.95346.77367.58352.42163.73127.3396.8283.51
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,921.811,932.081,882.801,875.482,399.461,664.23939.42392.19187.83
Total Shareholders Equity1,921.811,932.081,882.801,875.482,399.461,664.23939.42392.19187.83
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,921.811,932.081,882.801,875.482,399.461,664.23939.42392.19187.83
Total Liabilities & Stockholders Equity2,265.242,242.032,229.572,243.062,751.881,827.971,066.75489.02271.35
Book Value Per Share20.0422.5323.5223.8931.1722.5215.467.564.63
Tangible Book Value Per Share20.0422.5323.5223.8931.1622.5115.457.564.62
Full-Time Employees-393407458473410304188127
Price to Book Ratio2.651.732.881.632.436.803.943.785.30
Return on Assets-25.81-16.38-6.87-26.0316.49-24.108.59-43.40-22.18
Return on Equity-30.18-19.20-8.17-30.4218.59-26.8010.04-56.89-32.50
Return on Invested Capital-27.56-17.13-7.29-30.9114.46-20.356.80-42.07-36.39
Quick Ratio13.3222.0717.5415.3020.1718.2116.8616.8117.12
Current Ratio13.3222.0717.5415.3020.1718.2116.8616.8117.12

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-456.13-581.60-366.25-153.61-650.17377.66-348.8766.86-164.98
Depreciation18.5019.4819.2619.8424.1717.959.184.723.52
Other Funds (Non Cash)57.33145.2247.9566.98110.42116.5067.8833.5254.67
Funds from Operations-380.31-416.90-299.04-66.79-515.59512.11-271.81105.11-106.79
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.6871.88156.27-193.5919.8426.8633.44-48.4310.55
Cash from Operating Activities-374.63-345.01-142.77-260.38-495.74538.97-238.3756.68-96.24
Capital Expenditures-2.08-0.91-1.90-9.47-37.19-81.70-18.36-6.68-2.77
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.008.01-
Purchase or Sale of Investments-439.56-5.89-278.58386.62-221.47-953.73-522.810.000.00
Purchase of Investments-1,559.50-1,017.87-1,486.38-1,065.91-1,417.80-1,509.33-594.000.000.00
Sale Or Maturity of Investments1,119.941,011.981,207.801,452.531,196.33555.6071.190.000.00
Other Uses-1.65-25.000.00-2.500.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-443.29-31.80-280.48374.65-258.65-1,035.43-541.171.32-2.77
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock134.61426.03331.9862.6638.59250.941,016.15430.98315.93
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.06
Sale of Common Pref Stock134.61426.03331.9862.6638.59250.941,016.15430.98315.99
Proceedsfrom Stock Options110.77398.09300.6932.720.97213.27982.29415.02307.05
Issuance or Reduction of Debt, Net585.350.000.000.000.000.000.000.000.00
Change in Long Term Debt585.350.000.000.000.000.000.000.000.00
Issuance of Long Term Debt585.350.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities719.96426.03331.9862.6638.59250.941,016.15430.98315.93
Exchange Rate Effect-0.020.10-0.020.07-0.08-0.010.040.01-0.02
Net Change in Cash-97.9849.30-91.29177.01-715.88-245.52236.66489.00216.90
Free Cash Flow-376.71-345.93-144.68-269.85-532.93457.27-256.7249.99-99.01
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----13.32-69.36-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments2,272.932,364.732,442.181,983.461,919.221,724.75
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets12.157.046.182.219.878.91
Total Current Assets2,285.082,371.772,448.361,985.671,929.091,733.67
Net Property, Plant & Equipment226.91233.66240.85247.57255.49262.57
Total Investments and Advances43.5543.5334.837.6336.4230.61
Other Assets0.881.811.7824.3724.312.87
Total Assets2,556.412,650.772,725.822,265.242,245.312,029.71
Short Term Debt Incl. Current Port. of LT Debt18.6818.6518.6118.5818.2618.03
Accounts Payable20.5911.3113.6511.1411.809.75
Income Tax Payable0.130.490.641.113.430.71
Other Current Liabilities101.56102.45103.39118.2985.4875.87
Total Current Liabilities140.96132.90136.29149.12118.96104.36
Long Term Debt761.15765.10769.03188.17192.77197.43
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities6.246.225.956.1417.6016.80
Total Liabilities908.34904.22911.26343.43329.33318.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,648.071,746.551,814.561,921.811,915.981,711.12
Total Shareholders Equity1,648.071,746.551,814.561,921.811,915.981,711.12
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,648.071,746.551,814.561,921.811,915.981,711.12
Total Liabilities & Stockholders Equity2,556.412,650.772,725.822,265.242,245.312,029.71
Book Value Per Share17.0218.0718.8320.0420.4119.36
Tangible Book Value Per Share17.0218.0718.8320.0420.4119.36
Price to Book Ratio2.652.902.372.573.352.30
Return on Assets-19.00-19.28-23.24-25.81-21.70-21.41
Return on Equity-25.60-26.09-31.21-30.18-25.33-25.34
Return on Invested Capital-4.63-3.63-4.76-6.19-5.05-10.93
Quick Ratio16.2117.8517.9613.3216.2216.61
Current Ratio16.2117.8517.9613.3216.2216.61

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-111.44-91.15-122.93-130.61-106.44-208.55
Depreciation4.244.284.325.664.434.65
Other Funds (Non Cash)15.377.0725.129.766.46106.53
Funds from Operations-91.83-79.80-93.49-115.19-95.54-97.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.15-3.70-15.4122.6410.91-16.51
Cash from Operating Activities-89.68-83.50-108.90-92.55-84.63-113.88
Capital Expenditures-0.41-0.65-0.50-0.52-0.07-0.12
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-14.50-52.54-410.2437.72-119.1595.09
Purchase of Investments-330.80-215.03-750.70-262.97-334.09-215.08
Sale Or Maturity of Investments316.30162.49340.46300.69214.93310.18
Other Uses0.82-2.470.000.000.00-25.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-14.09-55.66-410.7437.20-119.2369.98
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-580.907.18591.91116.41296.772.26
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-580.907.18591.91116.41296.772.26
Proceedsfrom Stock Options-585.35-1.12585.75111.49278.11-0.02
Issuance or Reduction of Debt, Net585.350.000.000.000.000.00
Change in Long Term Debt585.350.000.000.000.000.00
Issuance of Long Term Debt585.350.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.457.18591.91116.41296.772.26
Exchange Rate Effect0.010.01-0.030.00-0.030.08
Net Change in Cash-99.31-131.9772.2461.0692.88-41.56
Free Cash Flow-90.10-84.15-109.40-93.07-84.71-114.00

Revenue breakdown

Collaboration2024: 35.00M
Grant2024: 2.31M 2025: 3.51M
Switzerland2024: 37.31M 2025: 3.51M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.09%17.2M90.1M1.52M
2026-10-1518.32%16.4M89.8M1.59M
2026-09-3020.81%18.7M89.8M1.60M
2026-09-1521.24%19.1M89.8M1.56M
2026-08-3120.91%18.8M89.8M1.64M
2026-08-1420.88%18.7M89.8M1.64M
2026-07-3120.96%18.8M89.8M1.71M
2026-07-1522.12%19.8M89.5M1.76M
2026-06-3022.78%20.4M89.5M1.73M
2026-06-1529.69%26.6M89.5M1.71M
2026-05-2924.20%21.7M89.5M1.91M
2026-05-1530.48%27.3M89.6M1.89M
2026-04-3025.12%22.5M89.5M1.90M
2026-04-1525.43%22.8M89.5M1.89M
2026-03-3125.39%22.6M89.1M1.94M
2026-03-1324.35%21.7M89.1M1.90M
2026-02-2724.21%21.6M89.1M1.72M
2026-02-1325.42%22.6M89.1M1.88M
2026-01-3023.87%21.9M91.7M2.03M
2026-01-1523.72%21.7M91.6M2.07M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call30.0014.0016.900.006.0410.000.000.930-0.4690.005
call35.009.0011.800.004.2750.000.000.902-0.4200.006
call39.005.007.807.213.0813.000.000.862-0.3640.007
call40.004.006.805.122.77412.005.000.847-0.3450.008
call41.003.005.805.252.49210.000.000.823-0.3330.009
call42.002.054.903.502.2785.000.000.780-0.3490.010
call43.001.303.803.401.8764.000.000.731-0.3420.011
call44.001.303.402.302.0208.005.000.640-0.3970.013
call45.000.751.451.000.95326.002.000.553-0.3310.013
call46.000.451.000.740.96338.0015.000.443-0.3560.013
call47.000.200.400.380.7471052.000.332-0.3120.012
call48.000.200.250.250.95834.003.000.228-0.2470.010
call49.000.000.450.201.14956.000.000.212-0.2980.010
call50.000.000.150.090.98811710.000.098-0.1420.006
call51.000.000.200.251.13062.000.000.088-0.1500.005
call52.000.000.850.051.2661060.000.080-0.1570.005
call53.000.052.000.111.3731030.000.075-0.1610.005
call54.000.002.150.051.39062.000.000.052-0.1240.004
call55.000.000.050.051.8911,1560.000.089-0.2480.005
call56.000.000.050.071.4231240.000.028-0.0760.002
call57.000.002.150.051.5291410.000.026-0.0780.002
call58.000.000.100.081.58241.000.000.041-0.0990.004
call59.000.002.150.101.71739.000.000.024-0.0800.002
call60.000.000.150.052.0221820.000.038-0.1370.003
call61.000.002.150.051.89818.000.000.022-0.0820.002
call62.000.002.150.501.9814.000.000.021-0.0830.002
call63.000.002.150.402.0654.000.000.020-0.0840.002
call64.000.002.150.102.14713.000.000.020-0.0850.002
call65.000.002.150.072.2279.000.000.019-0.0860.002
call66.000.002.150.002.3070.000.000.019-0.0870.002
call67.000.000.950.002.3930.000.000.018-0.0880.002
call68.000.000.050.052.1221540.000.018-0.0650.002
call70.000.000.050.052.24738.000.000.017-0.0660.002
call75.000.002.150.052.95724.000.000.015-0.0930.001
call80.000.002.150.053.26780.000.000.014-0.0960.001
put30.000.002.150.004.1770.000.00-0.070-0.4650.005
put35.000.002.150.002.9100.000.00-0.098-0.4160.006
put39.000.000.750.001.9790.000.00-0.137-0.3590.007
put40.000.000.750.051.73832.000.00-0.153-0.3400.008
put41.000.002.150.051.45011.000.00-0.168-0.3060.009
put42.000.000.500.191.2671.000.00-0.221-0.3450.010
put43.000.000.500.001.0250.000.00-0.271-0.3380.011
put44.000.050.600.350.85639.002.00-0.360-0.3920.013
put45.000.601.250.551.04315921.00-0.447-0.3260.013
put46.001.052.051.701.2401856.00-0.557-0.3510.013
put47.001.703.202.201.6441210.00-0.668-0.3070.012
put48.002.503.202.691.07480.002.00-0.772-0.2420.010
put49.002.355.103.672.07060.000.00-0.787-0.2930.010
put50.003.305.705.001.92439.000.00-0.902-0.1370.006
put51.004.907.005.752.3871221.00-0.933-0.1060.004
put52.006.007.506.672.12332.001.00-0.920-0.1510.005
put53.007.208.607.782.39540.000.00-0.926-0.1570.005
put54.008.2010.209.353.1454.001.00-0.931-0.1610.005
put55.009.2011.1010.403.19824.002.00-0.970-0.0690.002
put56.0010.2012.2011.323.4555.001.00-0.972-0.0700.002
put57.009.8013.708.574.08710.000.00-0.974-0.0710.002
put58.0010.8014.7010.884.2463.000.00-0.975-0.0730.002
put59.0012.2015.7011.804.3856.000.00-0.976-0.0740.002
put60.0012.8016.708.984.5491.000.00-0.977-0.0750.002
put61.0013.7017.700.004.6940.000.00-0.978-0.0760.002
put62.0014.7018.7017.044.8340.001.00-0.979-0.0770.002
put63.0016.1019.7017.974.9700.001.00-0.980-0.0780.002
put64.0016.7020.700.005.1020.000.00-0.980-0.0780.002
put65.0017.7021.7016.045.2310.000.00-0.981-0.0790.002
put66.0018.7022.700.005.3570.000.00-0.981-0.0800.002
put67.0019.7023.700.005.4790.000.00-0.982-0.0810.002
put68.0020.8024.700.005.5990.000.00-0.982-0.0810.001
put70.0022.7026.700.005.8290.000.00-0.983-0.0820.001
put75.0027.7031.700.006.3620.000.00-0.985-0.0850.001
put80.0032.8036.700.006.8440.000.00-0.986-0.0870.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-023Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-213Initial statement of beneficial ownership of securities2026-10-19SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2025-08-06SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-27SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10003.47M5
2026-09001.41M2
2026-080000
2026-070000
2026-060000
2026-0500210.58K1
2026-040000
2026-03002.75M9
2026-0200477.37K2
2026-01009.06M4
2025-1200559.55K1
2025-110000

Institutional holders

Manager% owned
ARK Investment Management LLC9.81%
BlackRock, Inc.8.66%
Orbis Allan Gray Ltd5.65%
Capital World Investors4.92%
STATE STREET CORP4.48%
GSK plc2.70%
GEODE CAPITAL MANAGEMENT, LLC2.60%
T. Rowe Price Investment Management, Inc.2.13%
SR ONE CAPITAL MANAGEMENT, LP2.11%
TWO SIGMA INVESTMENTS, LP2.06%

Funds

Fund% owned
iShares Convertible Bond ETF12.51%
State Street(R) SPDR(R) Bloomberg Convertible Securities ETF9.22%
Miller Market Neutral Income Fund6.22%
ARK Innovation ETF5.69%
Invesco Convertible Securities Fund3.11%
iShares Russell 2000 ETF2.48%
ARK Genomic Revolution ETF2.11%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.09%
New Perspective Fund2.02%
American Beacon SSI Alternative Income Fund1.78%

OakChart. CRSP. Cached 15 minutes.